Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
274 studies found for:    "Diffuse scleroderma"
Show Display Options
RSS Create an RSS feed from your search for:
"Diffuse scleroderma"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma
Condition: Systemic Sclerosis
Intervention: Drug: Relaxin
2 Recruiting IVIG Treatment in Systemic Sclerosis
Conditions: Systemic Sclerosis;   Diffuse Scleroderma
Intervention: Biological: Privigen
3 Recruiting Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma
Condition: Scleroderma
Interventions: Drug: atorvastatin;   Drug: Placebo
4 Terminated Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma
Condition: Scleroderma
Interventions: Drug: Imatinib mesylate;   Other: Placebo
5 Completed A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma
Conditions: Limited Scleroderma;   Diffuse Scleroderma
Intervention:
6 Recruiting Scleroderma Registry & Repository at the Hospital for Special Surgery
Condition: Scleroderma
Intervention:
7 Unknown  Nilotinib in the Treatment of Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention: Drug: Nilotinib (Tasigna)
8 Active, not recruiting Taking Charge of Systemic Sclerosis
Condition: Scleroderma
Interventions: Other: Internet-based self-management program;   Other: Scleroderma book
9 Completed Morbidity and Mortality Follow Up for the Scleroderma Lung Study
Condition: Scleroderma
Intervention: Other: Followup survey
10 Unknown  Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention: Drug: Imatinib Mesylate
11 Completed Angiogenic/Angiostatic Mediators in Patients With Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention:
12 Recruiting Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis
Condition: Scleroderma
Intervention: Drug: Campath
13 Terminated Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis
Condition: Scleroderma, Systemic
Interventions: Drug: Thalidomide;   Drug: Placebo thalidomide
14 Completed Stimulatory Autoantibodies to the Platelet-Derived Growth Factor Receptor (PDGFR) in Patients With Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention:
15 Active, not recruiting Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention: Drug: Belimumab
16 Completed
Has Results
Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement
Condition: Scleroderma, Systemic
Intervention: Drug: Mycophenolate mofetil
17 Recruiting Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial
Condition: Scleroderma
Interventions: Procedure: Cytoxan rATG/Fludarabine/HSCT;   Procedure: Cytoxan rATG/HSCT
18 Completed Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
Condition: Systemic Scleroderma
Interventions: Drug: C-82 Topical Gel, 1%;   Drug: C-82 Topical Gel, Placebo
19 Recruiting Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis
Conditions: Systemic Scleroderma;   Severe Systemic Sclerosis
Interventions: Drug: fludarabine phosphate;   Drug: Mycophenolic Acid;   Drug: tacrolimus;   Radiation: total-body irradiation;   Procedure: bone marrow transplantation;   Procedure: reduced intensity allogeneic hematopoietic stem cell transplantation;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Procedure: biopsy;   Drug: cyclophosphamide
20 Completed
Has Results
High Dose Cyclophosphamide for Treatment of Scleroderma
Condition: Scleroderma
Intervention: Drug: IV Cyclophosphamide

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.